Pharmosa Biopharm Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	324.12	314.5	-	-	-
Gross Profit	317.23	314.5	-	-	-
Selling, General & Admin	52.84	40.35	29.22	18.32	12.11
Research & Development	274.24	276.97	242.31	240.81	175.31
Operating Expenses	327.08	317.32	271.53	259.12	187.42
Operating Income	-9.85	-2.82	-271.53	-259.12	-187.42
Interest Expense	-3.48	-2.86	-0.65	-1.21	-3.86
Interest & Investment Income	21.03	9.53	0.5	0.1	0.04
Earnings From Equity Investments	4.92	5.5	3.93	0.66	4.63
Currency Exchange Gain (Loss)	9.3	-6.68	1.02	0.2	0.96
Other Non Operating Income (Expenses)	6.01	5.79	0.23	2.89	3.96
Pretax Income	27.78	8.46	-266.51	-256.48	-181.7
Net Income	27.78	8.46	-266.51	-256.48	-181.7
Net Income to Common	27.78	8.46	-266.51	-256.48	-181.7
Shares Outstanding (Basic)	120	113	99	85	48
Shares Outstanding (Diluted)	120	113	99	85	48
Shares Change (YoY)	14.02%	15.09%	16.02%	78.34%	-
EPS (Basic)	0.23	0.07	-2.70	-3.02	-3.82
EPS (Diluted)	0.23	0.07	-2.70	-3.02	-3.82
Free Cash Flow	-93.45	-39.04	-268.47	-240.57	-188.5
Free Cash Flow Per Share	-0.78	-0.34	-2.72	-2.83	-3.96
Gross Margin	97.87%	100.00%	-	-	-
Operating Margin	-3.04%	-0.90%	-	-	-
Profit Margin	8.57%	2.69%	-	-	-
Free Cash Flow Margin	-28.83%	-12.41%	-	-	-
EBITDA	-0.57	2.99	-266.24	-254.73	-184.2
EBITDA Margin	-0.17%	0.95%	-	-	-
D&A For EBITDA	9.28	5.81	5.3	4.39	3.22
EBIT	-9.85	-2.82	-271.53	-259.12	-187.42
EBIT Margin	-3.04%	-0.90%	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.